Dr. Lan GuoCheng, Founder of Genome Technologies Limited, Co-published a Research Article on PNAS
Hong Kong, December 23, 2025—Dr. Lan GuoCheng, the founder of Genome Technologies Limited has co-published a new research article “The kinesin-4 protein KIF27 forms a cytoskeletal scaffold at the transition zone to promote motile cilia structural integrity” along side with 19 scientists, on the Proceedings of the National Academy of Sciences of the United States of America (PNAS).
The article can be found here: https://www.pnas.org/doi/10.1073/pnas.2515392122
Genome Technologies Limited Selected to Join Hong Kong Science Park
Hong Kong, May 16, 2025 — Genome Technologies Limited (hereinafter referred to as "Genome Tech") announced today that after a rigorous review and selection process, the company has been formally approved to join the Hong Kong Science Park and has been admitted as an incubatee of the Hong Kong Science and Technology Parks Corporation (HKSTP) "Incu-Bio Programme." This milestone signifies that Genome Tech's innovative capabilities and development potential in the biomedical field have received authoritative recognition. Moving forward, the company will leverage the world-class research ecosystem of the Hong Kong Science Park to accelerate the development and commercialization of its cutting-edge technologies.
As a leading technology and innovation hub in Asia, the Hong Kong Science Park brings together top global biotech enterprises and research institutions. Its "Incu-Bio Programme" aims to support high-potential biopharmaceutical startups through funding, technology transfer guidance, and industry resource connections, helping them to grow rapidly. Genome Tech stood out among numerous candidates with its innovative technology platform and forward-looking R&D pipeline, becoming a key incubatee of the programme.
Genome Technologies Limited is a biotechnology company focused on providing highly efficient gene-edited animal models. It is committed to deliver genomically modified animals quickly and efficiently through AI-assisted stem cell editing technologies. For example, the production and delivery time for gene knockout and point mutation mice has been significantly reduced to one-third of that of other market benchmark companies, resulting in substantial efficiency gains. This has broad application prospects in disease model research, drug development, and drug efficacy validation, with the goal of becoming a leader in the gene-edited animal market. After joining the Hong Kong Science Park, the company will gain access to advanced laboratory facilities, a cross-disciplinary expert network, and international collaboration opportunities, further accelerating technology implementation and global market expansion.
"We are honored to join the innovation ecosystem of the Hong Kong Science Park," said Dr. Lan Guocheng, Founder and CEO of Genome Tech. "This collaboration will provide us with crucial resources and support, helping our team translate scientific breakthroughs into practical solutions for biomedical R&D. Hong Kong, as a bridge connecting Mainland China and global markets, will also offer unique advantages for our internationalization strategy."
About Genome Technologies Limited:
Established in 2023, Genome Tech is a high-tech enterprise specializing in R&D, production, and sales of experimental animal models. The company has gathered a team of highly qualified professionals with diverse backgrounds in biology, medicine, AI, and other disciplines.
Genome Technologies Limited aims to use precise and efficient gene-editing technologies to enable researchers to quickly obtain high-quality model animals, providing strong support for scientific research and therapeutic drug development.
The company has already secured multiple patents and established an AI-assisted design system and a gene-editing technology platform. It has established comprehensive experimental animal research centers in Hong Kong, Shenzhen, and Chongqing, including small animal breeding centers primarily for mice and large animal breeding centers primarily for pigs. These centers are equipped with drug efficacy, pharmacological mechanism, drug metabolism, and safety evaluation platforms for drug R&D, offering clients efficient end-to-end services. Genome Tech looks forward to creating a better future together with global pharmaceutical R&D and life science researchers.
About the HKSTP "Incu-Bio Programme":
This programme is a specialized incubation platform designed by the Hong Kong Science Park for early-stage biopharmaceutical enterprises. It provides up to four years of funding and comprehensive support, covering R&D funding, intellectual property consultation, medical device and drug application assistance, and investment and financing connections, helping enterprises transition from the laboratory to the market.